Close
Close

DEKK-TEC, Inc. - Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer

Partner

Not provided

Rare Disease

Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer

Sponsor

DEKK-TEC, Inc.

Access Program Information

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain via Pgp (p-glycoprotein) (1). DM-CHOC-PEN has completed Phase I/II trials in humans with primary and secondary tumors involving the brain with success. Complete remissions in both primary (astrocytomas, GBM) and metastatic lung cancers. This trial is open for pediatric and adolescent subjects with advanced cancer - brain involvement is not required.

Contact

Contact: Lee Roy Morgan, MD, PhD (5045836135)

Locations
  • United States
  • Detroit, Michigan, United States
  • United States
  • Cincinnati, Ohio, United States

Free Newsletter